Candel Therapeutics, Inc.
CADL
$9.79
$0.323.38%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 34.87% | 0.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.42% | 19.22% | |||
| Operating Income | -3.42% | -19.22% | |||
| Income Before Tax | 69.96% | -161.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 69.96% | -161.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 69.96% | -161.74% | |||
| EBIT | -3.42% | -19.22% | |||
| EBITDA | -3.55% | -19.75% | |||
| EPS Basic | 73.55% | -161.71% | |||
| Normalized Basic EPS | 73.55% | -161.65% | |||
| EPS Diluted | 73.55% | -161.71% | |||
| Normalized Diluted EPS | 73.55% | -161.65% | |||
| Average Basic Shares Outstanding | 13.60% | 0.01% | |||
| Average Diluted Shares Outstanding | 13.60% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||